Cover Image
市場調查報告書

中東、北非的醫藥品、醫療產業 (季度更新報告)

Middle East and North Africa Pharmaceuticals and Healthcare Report Q1 2017

出版商 BMI Research 商品編碼 361671
出版日期 內容資訊 英文 31 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
中東、北非的醫藥品、醫療產業 (季度更新報告) Middle East and North Africa Pharmaceuticals and Healthcare Report Q1 2017
出版日期: 2017年01月18日 內容資訊: 英文 31 Pages
簡介

本報告提供中東、北非 (MENA) 各國的製藥、醫療產業結構和形勢相關分析,最新的市場趨勢 (以季度為基礎) ,及今後的長期性的產業規模的動向估計,產業的課題 (風險) 和未來商機 (利潤) 相關評估,今後的市場成長的機會與課題,域內各國、各地區詳細趨勢,主要企業簡介等資訊彙整,為您概述為以下內容。

BMI產業分析

  • 中東、北非市場最新趨勢 (以季度為基礎)

SWOT分析

  • 中東、北非市場最新趨勢 (以季度為基礎)

產業預測

  • 製藥產業:中東、北非市場最新趨勢 (以季度為基礎)
  • 醫療產業:中東、北非市場最新趨勢 (以季度為基礎)

產業的風險/利潤指標

  • 中東、北非市場最新趨勢 (以季度為基礎)

市場概要

  • 中東、北非市場最新趨勢 (以季度為基礎)

產業的趨勢與發展

  • 中東、北非市場最新趨勢 (以季度為基礎)

地區概要

  • 中東、北非市場最新趨勢 (以季度為基礎)

用語一覽

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、等級技術
  • 指標概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 2398-1040

BMI View: Opportunities for international drugmakers within the Middle East and North Africa (MENA)

region's pharmaceutical and healthcare markets will remain robust. As highlighted in recent quarterly

financial earnings, the region's commercial potential remains significant and presents an alluring

opportunity for companies shifting their focus onto emerging market growth strategies. However, as the

lasting effects of weak economic growth, low oil prices and slower public consumption are drawn out, we

expect this to weigh on pharmaceutical market growth in the region over the coming years. Indeed, the

MENA region will remain a challenging, yet commercially attractive, environment for multinational

drugmakers.

Headline Expenditure Projections

  • Pharmaceuticals: USD32.0bn in 2015 to USD30.2bn in 2016; a -5.6% y-o-y change in US dollar terms.
  • Healthcare: USD170.4bn in 2015 to USD171.6bn in 2016; a +0.7% y-o-y change in US dollar terms.

Risk/Reward Index

In BMI's Q117 Risk/Reward Index (RRI), the Middle East and North Africa (MENA) scores 48.1 out of

100, comparing relatively poorly with Europe (58.4), Asia Pacific (51.2), and the Americas (50.6).

However, MENA scores well in comparison to Sub-Saharan Africa (32.5). The indicators used to assess the

attractiveness of a pharmaceutical market are now visible, improving the transparency of the index system

and enabling the identification of regional or group outperformers across single indicators.

Table of Contents

  • BMI Industry View
  • Middle East And North Africa - Q1 2017
    • Table: Headline Regional Pharmaceuticals & Healthcare Forecasts (2014-2020)
  • SWOT
  • Middle East And North Africa - Q1 2017
  • Industry Forecast
  • Pharmaceutical - Middle East And North Africa - Q1 2017
    • Table: Regional Pharmaceutical Sales, Historical Data And Forecasts (2012-2020)
  • Healthcare - Middle East And North Africa - Q1 2017
    • Table: Regional Pharmaceutical Sales, Historical Data And Forecasts (2012-2020)
  • Industry Risk Reward Index
  • Middle East And North Africa Risk/Reward Index - Q1 2017
  • Market Overview
  • Middle East And North Africa - Q1 2017
  • Regional Overview
  • Middle East & North Africa - Q1 2017
  • Industry Trends And Developments
  • Regional Round-Up Q1 2017
  • Glossary
  • Methodology
  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top